Related Experiment Video

Updated: Jun 21, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

Fever and neutropenia in pediatric patients with cancer

Garth Meckler1, Susan Lindemulder

  • 1Department of Emergency Medicine, Oregon Health & Science University, CDW-EM, Portland, OR 97239-3098, USA. mecklerg@ohsu.edu

Emergency Medicine Clinics of North America
|August 4, 2009
PubMed

Insights

Aggressive cancer treatments can cause neutropenia (low white blood cell counts) in children, increasing infection risk. This review covers evaluating and managing febrile neutropenic pediatric cancer patients.

Area of Science:

  • Pediatric Oncology
  • Hematology

Background:

  • Childhood cancer treatments like chemotherapy and radiation can harm bone marrow cells.
  • This harm often leads to neutropenia, a condition increasing infection risk and mortality in pediatric cancer patients.

Purpose of the Study:

  • To review the current understanding of febrile neutropenia in pediatric cancer patients.
  • To discuss the evaluation and management strategies for this critical condition.

Main Methods:

  • Review of existing literature and clinical guidelines.
  • Analysis of risk stratification criteria for febrile neutropenia.
  • Discussion of antibiotic treatment protocols.

Main Results:

  • Risk stratification helps differentiate high- and low-risk pediatric patients.
  • Development of broad-spectrum antibiotics has improved treatment outcomes.
  • Management strategies have evolved based on defined criteria and improved therapies.

Conclusions:

  • Effective management of febrile neutropenia in pediatric cancer relies on risk assessment and timely antibiotic therapy.
  • Continued research is essential to further improve outcomes for these vulnerable patients.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Methods of reducing fever01:22

Methods of reducing fever

The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...